Jove
Visualize
联系我们

相关概念视频

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策
  1. 首页
  3. 骨矿物质密度预测肝细胞癌和门静脉瘤患者的存活率
  1. 首页
  3. 骨矿物质密度预测肝细胞癌和门静脉瘤患者的存活率

相关实验视频

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
07:35

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Published on: December 26, 2016

41.5K

骨矿物质密度预测肝细胞癌和门静脉瘤患者的存活率

Lukas Müller1,2, Roman Kloeckner3, Lorena Heim1

  • 1Department of Diagnostic and Interventional Radiology, University Medical Center Mainz, Mainz, Germany.

PloS one
|August 22, 2025

在PubMed 上查看摘要

概括
此摘要是机器生成的。

骨矿物质密度 (BMD) 是肝细胞癌 (HCC) 和门静脉瘤 (PVTT) 患者生存的重要预测因素. 在这个患者群体中,较高的骨质量水平与较长的整体存活率相关.

更多相关视频

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

6.5K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.5K

相关实验视频

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
07:35

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Published on: December 26, 2016

41.5K
Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

6.5K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.5K

科学领域:

  • 癌症学
  • 放射学
  • 骨质新陈代谢

背景情况:

  • 肝细胞癌 (HCC) 是癌症死亡的主要原因.
  • 门静脉瘤 (PVTT) 是HCC的常见并发症,使患者的预后恶化.
  • 骨矿物密度 (BMD) 是HCC的新兴预后因素,但其在PVTT中的作用尚不清楚.

研究的目的:

  • 调查HCC和PVTT患者的骨髓质质量预后值.
  • 确定 BMD 是否可以独立预测该特定患者队列的存活率.

主要方法:

  • 对462名HCC和PVTT患者的回顾性分析 (2005 - 2020年).
  • 使用计算机断层扫描在L1 (Hounsfield单位,HU) 测量骨质量.
  • 卡普兰-梅尔生存分析和多变量考克斯回归.

主要成果:

  • 在HCC诊断时,中位 BMD 为 136 HU,在PVTT发病时为 134 HU.
  • 患者的整体存活时间显著延长 (10. 4 vs 5.5 个月在HCC诊断; 8. 5 vs 4. 7 个月在PVTT发病).
  • 瘤生长模式,治疗和ALBI等级是生存的独立预测指标.

结论:

  • 在HCC和PVTT患者中,骨质量是生存的独立预后因素.
  • 在预后模型中纳入BMD可以改善患者分层和治疗决策.
  • 进一步的研究可以探索BMD和HCC-PVTT结果之间的联系机制.